

Corporate Action Notice



April 5, 2013

Ratio Change and Stock Distribution Notice

*****This event was approved at the General Meeting held on March 26, 2013 / Updated Notice*****

Outotec
DR CUSIP: 69011X109
DR ISIN: FI0009014575
DR Ticker Symbol: OUKPY
Ratio (DRs: Underlying Shares): 5:1

Further to our notice dated March 19, 2013, we advised that Outotec has announced a stock distribution in the local market of three new shares for each existing share held (or a 4 for 1 forward split) as of the local record date of April 2, 2013.

As a result, effective April BNY Mellon will change the ratio on the Outotec Depository Receipts ("DR") program from 5 DRs representing 1 ordinary share to 2 DRs representing 1 ordinary share.

The ratio change will occur simultaneously with a 60% DSs distribution (or 0.60 additional DSs for each 1 DS held). DR holders will be charged an issuance fee of \$0.05 per DS issued.

Please note the following:

DR Record Date: April 2, 2013
DR Payable Date: April 10, 2013
DR Distribution Rate: 60% Distribution (or 0.60 additional DSs for each 1 DS held).
Old DR Ratio: 5 DRs : 1 Underlying Share
New DR Ratio: 2 DRs : 1 Underlying Share
Effective date for DR ratio change: April 11, 2013

Books will be closed from April 3, 2013 **and will reopen on April 16, 2013 for Issuance and Cancellation transactions.**

To learn more about Depository Receipts and issuer programs, please contact our marketing desks:

New York

Ravi Davis
Vice President
+1 212 815-4245
Ravi.davis@bnymellon.com

London

Damon Rowan
Vice President
+44 207 964 6527
damon.rowan@bnymellon.com

Hong Kong

Joe Oakenfold
Vice President
+852 2 840 9717
joe.oakenfold@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.